Last reviewed · How we verify

Almonertinib combined with SHR-1701 — Competitive Intelligence Brief

Almonertinib combined with SHR-1701 (Almonertinib combined with SHR-1701) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline.

phase 1 Small molecule Live · refreshed every 30 min

Target snapshot

Almonertinib combined with SHR-1701 (Almonertinib combined with SHR-1701) — Suzhou Suncadia Biopharmaceuticals Co., Ltd..

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Almonertinib combined with SHR-1701 TARGET Almonertinib combined with SHR-1701 Suzhou Suncadia Biopharmaceuticals Co., Ltd. phase 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Almonertinib combined with SHR-1701 — Competitive Intelligence Brief. https://druglandscape.com/ci/almonertinib-combined-with-shr-1701. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: